Breaking News Instant updates and real-time market news.

HZNP

Horizon Pharma

$21.90

0.03 (0.14%)

, NVS

Novartis

$88.23

-0.1 (-0.11%)

10:07
11/14/18
11/14
10:07
11/14/18
10:07

Horizon Pharma strength continues amid Novartis takeover speculation

Shares of Horizon Pharma (HZNP) have continued to move higher and built upside momentum after traders circulated chatter that Novartis (NVS) may be interested in acquiring the company. The Fly, in fulfilling its mission of explaining stock movement, often comes across the many unconfirmed rumors being passed through trading desks and social media platforms. On the occasion that rumors or speculation appear on The Fly's news feed, it should be viewed not as giving credence to the conjecture, rather as simply highlighting its impact on the stock prices of the companies involved. The Fly has reached out to Horizon Pharma for comment. Shares of Horizon Pharma have risen $1.15, or 5.3%, to $23.00 in early morning trading.

HZNP

Horizon Pharma

$21.90

0.03 (0.14%)

NVS

Novartis

$88.23

-0.1 (-0.11%)

  • 14

    Nov

  • 14

    Nov

  • 15

    Nov

  • 27

    Nov

  • 03

    Dec

HZNP Horizon Pharma
$21.90

0.03 (0.14%)

11/01/18
STFL
11/01/18
NO CHANGE
Target $35
STFL
Buy
Horizon Pharma price target raised to $35 from $25 at Stifel
After hosting a call with a leading oculoplastic surgeon, Stifel analyst Annabel Samimy said she gained further confidence in her view that teprotumumab will have clinical success in Phase 3 and, more importantly, commercial success. Assuming a "high probability of success" of about 85% for teprotumumab, she raised her price target for Horizon Pharma shares to $35 from $25 and keeps a Buy rating on the stock.
10/23/18
STFL
10/23/18
NO CHANGE
STFL
Buy
Selecta SEL-212 data 'very competitive to Krystexxa mono/combo therapy, says Stifel
Stifel analyst Derek Archila views Selecta Biosciences (SELB) SEL-212 Phase 2 data in chronic severe gout as positive and thinks it represents a "very competitive" emerging profile relative to the incumbent brand, Horizon Pharma's (HZNP) Krystexxa. The analyst comes away positive with the fact SEL-212's projected response rate remains competitive on a modified intent-to-treat basis, SVP-Rapamycin was tolerable out to five months of dosing, and SEL-212's rate of gout flares was lower than Krystexxa alone and Krystexxa+methotrexate early on. Archila remains positive on the stock and believes SEL-212 could offer an improvement to the current standard of care for chronic severe gout. Further, Archila does not believe shares fully reflect the program's commercial potential and reiterates a Buy rating on Selecta's shares.
10/23/18
MZHO
10/23/18
NO CHANGE
Target $30
MZHO
Buy
Selecta stock reaction to SEL-212 data 'overly negative,' says Mizuho
Mizuho analyst Difei Yang believes the market reaction to Selecta Biosciences' (SELB) Phase 2 data on SEL-212 is "overly negative," stating that she believe it is likely acceptable to the FDA to proceed into Phase 3. While not as good as she had hoped for, she still sees the data remaining superior to standalone Krystexxa, marketed by Horizon Pharma (HZNP), "especially considering stringent stopping rules and evaluation criteria in the trial," Yang tells investors. She keeps a Buy rating and $30 price target on Selecta shares.
10/23/18
COWN
10/23/18
NO CHANGE
Target $25
COWN
Outperform
Cowen says Horizon positive news about Krystexxa competitor outweighs 340(B)
After Selecta Biosciences (SELB) released "disappointing" data from its potential competitive program to Horizon Pharma's (HZNP) Krystexxa, Cowen analyst Ken Cacciatore said the news "virtually eliminates [SEL-212] as a threat" and far outweighs the modestly negative potential 340(B) timing change. While HHS is proposing to change the date on which 340(B) pricing would come into effect from July 1, 2019, to January 1, 2019, Cacciatore called this news "largely irrelevant" since his model for Horizon already assumed adjustments to the program beginning in July 2019, he added. He contends that the net of these two disclosures should be viewed "much more positively than negatively" and would be adding to Horizon positions, Cacciatore tells investors. He keeps an Outperform rating on Horizon Pharma shares with a $25 price target.
NVS Novartis
$88.23

-0.1 (-0.11%)

10/29/18
MSCO
10/29/18
NO CHANGE
MSCO
Equal Weight
Morgan Stanley sees little impact to Regeneron from competitor data at AAO
Morgan Stanley analyst Matthew Harrison noted that data was presented at the American Academy of Ophthalmology's annual meeting for three potential competitors to Regeneron's (REGN) Eylea - Allergan's (AGN) abicipar pegol, Novartis' (NVS) brolucizumab and Roche's (RHHBY) faricimab. Following the presentations, his view on abicipar and brolucizumab is unchanged and he awaits further late-stage data from faricimab, said Harrison, who sees little impact to Regeneron based on the new data. He maintains an Equal Weight rating on Regeneron shares.
10/29/18
PIPR
10/29/18
NO CHANGE
Target $73
PIPR
Overweight
Glaukos remains 'compelling' name that should be owned, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien says feedback on Glaukos' (GKOS) iStent and Inject was again positive at this weekend's American Academy of Ophthalmology meeting. The products are "proving very safe and efficacious," O'Brien tells investors in a research note. Further, the analyst says he has not heard much, if any, commentary on a procedural slowdown of other microinvasive glaucoma surgery cases following the withdrawal of Novartis' (NVS) CyPass, which he believes should be a positive for Glaukos. O'Brien continues to view Glaukos as a "compelling med tech name that should be owned here." He keeps an Overweight rating on the shares with a $73 price target.
10/25/18
WELS
10/25/18
NO CHANGE
WELS
Wells Fargo says Trump speech today won't be end of drug pricing proposals
Wells Fargo analyst David Maris notes that Politico and other media outlets are reporting that President Donald Trump will propose several new initiatives to address high drug prices when he speaks later today at the U.S. Department of Health and Human Services. Maris thinks Trump's focus will be on how other countries are "freeloading" on U.S. innovation with lower negotiated pricing, stating that news reports make it appear that the administration is targeting the industry for action, rather than other countries to raise their spending. While Maris acknowledges the timing of the speech being near the mid-term elections, he believes these proposals are simply the follow-though of earlier promises. He also expects this is not the end of proposals to address the issue of U.S. drug pricing. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
10/23/18
WOLF
10/23/18
INITIATION
WOLF
Outperform
Novartis reinitiated with an Outperform at Wolfe Research
Wolfe Research analyst Time Anderson reinitiated Novartis with an Outperform.

TODAY'S FREE FLY STORIES

CBS

CBS

$43.83

0.5 (1.15%)

, VIA

Viacom

$27.27

-0.4 (-1.45%)

08:03
08/17/19
08/17
08:03
08/17/19
08:03
Periodicals
Viacom-CBS merger got panned by investors, Barron's says »

CBS (CBS) and Viacom…

CBS

CBS

$43.83

0.5 (1.15%)

VIA

Viacom

$27.27

-0.4 (-1.45%)

VIAB

Viacom

$26.02

0.09 (0.35%)

AAPL

Apple

$206.44

4.71 (2.33%)

DIS

Disney

$135.19

1.79 (1.34%)

T

AT&T

$34.98

0.64 (1.86%)

CMCSA

Comcast

$43.17

0.82 (1.94%)

CMCSK

Comcast

$0.00

(0.00%)

NFLX

Netflix

$302.74

6.81 (2.30%)

AMZN

Amazon.com

$1,791.82

16.72 (0.94%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 05

    Sep

  • 23

    Sep

  • 23

    Oct

  • 27

    Oct

MYGN

Myriad Genetics

$25.36

2.14 (9.22%)

07:57
08/17/19
08/17
07:57
08/17/19
07:57
Periodicals
Myriad Genetics stock might have an FDA issue, Barron's says »

Myriad Genetics plunged…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

CSCO

Cisco

$46.96

0.73 (1.58%)

, NTAP

NetApp

$46.75

0.33 (0.71%)

07:50
08/17/19
08/17
07:50
08/17/19
07:50
Periodicals
Trade war hitting tech stocks, Barron's says »

Cisco (CSCO) plunged 9% a…

CSCO

Cisco

$46.96

0.73 (1.58%)

NTAP

NetApp

$46.75

0.33 (0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 12

    Sep

  • 10

    Oct

  • 13

    Nov

RDS.A

Royal Dutch Shell

$55.55

0.47 (0.85%)

, RDS.B

Royal Dutch Shell

$55.56

0.46 (0.83%)

07:47
08/17/19
08/17
07:47
08/17/19
07:47
Periodicals
Investors should not abandon oil, gas stocks, Barron's says »

Energy stocks have rarely…

RDS.A

Royal Dutch Shell

$55.55

0.47 (0.85%)

RDS.B

Royal Dutch Shell

$55.56

0.46 (0.83%)

BP

BP

$36.27

0.22 (0.61%)

XOM

Exxon Mobil

$68.30

1.06 (1.58%)

CVX

Chevron

$115.79

0.08 (0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 25

    Sep

TGT

Target

$84.20

1.67 (2.02%)

, WMT

Walmart

$112.99

0.32 (0.28%)

07:40
08/17/19
08/17
07:40
08/17/19
07:40
Periodicals
Grocery Outlet thriving as rivals struggle, Barron's says »

While Dow was down 800…

TGT

Target

$84.20

1.67 (2.02%)

WMT

Walmart

$112.99

0.32 (0.28%)

GO

Grocery Outlet

$46.55

2.81 (6.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 15

    Sep

  • 19

    Sep

  • 25

    Sep

  • 13

    Nov

  • 14

    Nov

AEO

American Eagle

$15.40

0.63 (4.27%)

07:33
08/17/19
08/17
07:33
08/17/19
07:33
Periodicals
American Eagle to soar despite trade war, Barron's says »

American Eagle's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 25

    Sep

ANGI

Angi Homeservices

$8.18

-0.18 (-2.15%)

, MTCH

Match Group

$84.53

2.08 (2.52%)

07:27
08/17/19
08/17
07:27
08/17/19
07:27
Periodicals
Dating business might be IAC's best asset, greatest challenge, Barron's says »

IAC (IAC) has rallied 34%…

ANGI

Angi Homeservices

$8.18

-0.18 (-2.15%)

MTCH

Match Group

$84.53

2.08 (2.52%)

IAC

IAC

$249.17

4.21 (1.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 10

    Sep

  • 10

    Oct

AAPL

Apple

$206.44

4.71 (2.33%)

, HAS

Hasbro

$114.29

1.13 (1.00%)

07:13
08/17/19
08/17
07:13
08/17/19
07:13
On The Fly
Week in review How Trump's policies moved stocks »

Catch up on the top…

AAPL

Apple

$206.44

4.71 (2.33%)

HAS

Hasbro

$114.29

1.13 (1.00%)

MAT

Mattel

$10.74

(0.00%)

AGR

Avangrid

$49.29

0.37 (0.76%)

JPM

JPMorgan

$107.73

2.52 (2.40%)

BAC

Bank of America

$27.04

0.79 (3.01%)

C

Citi

$63.46

2.13 (3.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

  • 09

    Sep

  • 02

    Oct

  • 15

    Oct

  • 15

    Oct

  • 16

    Oct

  • 27

    Oct

NCLH

Norwegian Cruise Line

$50.48

1.38 (2.81%)

18:04
08/16/19
08/16
18:04
08/16/19
18:04
Hot Stocks
Norwegian Cruise Line CEO sells 25K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RM

Regional Management

$27.12

0.14 (0.52%)

18:01
08/16/19
08/16
18:01
08/16/19
18:01
Hot Stocks
Regional Management CFO buys 5K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

RTN

Raytheon

$178.10

-0.42 (-0.24%)

17:59
08/16/19
08/16
17:59
08/16/19
17:59
Hot Stocks
Raytheon awarded $199.59M Navy contract for MK 15 CIWS »

Raytheon has been awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WEN

Wendy's

$19.94

0.16 (0.81%)

17:57
08/16/19
08/16
17:57
08/16/19
17:57
Hot Stocks
Breaking Hot Stocks news story on Wendy's »

Trian Fund lowers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

BRY

Berry Petroleum

$8.59

0.39 (4.76%)

17:54
08/16/19
08/16
17:54
08/16/19
17:54
Syndicate
Breaking Syndicate news story on Berry Petroleum »

Berry Petroleum files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSWI

CSW Industrials

$70.20

1.92 (2.81%)

17:52
08/16/19
08/16
17:52
08/16/19
17:52
Hot Stocks
CSW Industrials CEO sells 25K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OAS

Oasis Petroleum

$3.03

0.135 (4.66%)

17:49
08/16/19
08/16
17:49
08/16/19
17:49
Hot Stocks
Oasis Petroleum CEO buys 30K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EE

El Paso Electric

$66.41

0.005 (0.01%)

17:45
08/16/19
08/16
17:45
08/16/19
17:45
Hot Stocks
El Paso Electric director Wertheimer sells 25K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HON

Honeywell

$165.07

2.81 (1.73%)

17:42
08/16/19
08/16
17:42
08/16/19
17:42
Hot Stocks
Honeywell CEO sells 7.1K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MBRX

Moleculin Biotech

$1.08

0.01 (0.93%)

17:37
08/16/19
08/16
17:37
08/16/19
17:37
Earnings
Moleculin Biotech reports Q2 EPS (3c), two estimates (10c) »

CFO Jonathan Foster…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIVE

Viveve

$0.13

0.0046 (3.59%)

17:35
08/16/19
08/16
17:35
08/16/19
17:35
Syndicate
Breaking Syndicate news story on Viveve »

Viveve files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRGO

Perrigo

$46.21

0.535 (1.17%)

17:30
08/16/19
08/16
17:30
08/16/19
17:30
Hot Stocks
Breaking Hot Stocks news story on Perrigo »

Starboard lowers Perrigo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

UAL

United Continental

$82.96

1.36 (1.67%)

17:28
08/16/19
08/16
17:28
08/16/19
17:28
Hot Stocks
United Continental director Shapiro buys 10K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 05

    Sep

  • 23

    Sep

MBIO

Mustang Bio

$3.88

0.19 (5.15%)

17:26
08/16/19
08/16
17:26
08/16/19
17:26
Syndicate
Breaking Syndicate news story on Mustang Bio »

Mustang Bio files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

BCLI

BrainStorm

$3.63

0.055 (1.54%)

17:24
08/16/19
08/16
17:24
08/16/19
17:24
Syndicate
Breaking Syndicate news story on BrainStorm »

BrainStorm files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WLK

Westlake Chemical

$61.27

0.66 (1.09%)

17:15
08/16/19
08/16
17:15
08/16/19
17:15
Hot Stocks
Westlake Chemical raises quarterly dividend by 5% to 26.25c per share »

The dividend will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIG

GigCapital

$10.30

(0.00%)

17:10
08/16/19
08/16
17:10
08/16/19
17:10
Hot Stocks
GigCapital receives noncompliance notice from NYSE »

GigCapital announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.